
|Podcasts|June 8, 2010
Value in Oncology, an Interview with Marty Neltner
Author(s)Marty Neltner
In this exclusive CancerNetwork Blog podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.
Advertisement
In this exclusive Cancer Network podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.
Given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume. In oncology's world, that translates into value over chemo reimbursement.
-Interviewed by Ron Piana
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement





131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
2
Cevostamab May Fill Gap in Multiple Myeloma Armamentarium
3
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
4
FDA Accepts Protocol Amendment to Phase 3 NANORAY-312 Trial in HNSCC
5













































